Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR9 | P51686 | 1/20 | 0.33 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.32 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21390951 | 1.00 | CCR9 (0.33) | CCR9AGTR1AGTR2APEX1TBXA2R | |
| SCHEMBL21390751 | 0.88 | CCR9 (0.32) | CCR9HDAC6 | |
| SCHEMBL21390915 | 0.87 | CES1 (0.33) | APEX1HDAC6 | |
| SCHEMBL21390773 | 0.84 | MEN1 (0.35) | CCR9AGTR1AGTR2APEX1LMNA | |
| SCHEMBL21390835 | 0.81 | OXER1 (0.32) | AGTR1AGTR2ATMSMN1; SMN2HDAC6 | |
| SCHEMBL21391133 | 0.81 | CYP11B1 (0.33) | LMNASMN1; SMN2 | |
| SCHEMBL21391160 | 0.78 | ACSS2 (0.38) | AGTR1AGTR2APEX1TBXA2RHDAC6 | |
| SCHEMBL21391173 | 0.76 | ACSS2 (0.36) | AGTR1AGTR2TBXA2RHDAC6 | |
| SCHEMBL20624562 | 0.76 | CCR9 (0.35) | CCR9LMNASMN1; SMN2 | |
| SCHEMBL19276105 | 0.76 | CCR9 (0.35) | CCR9LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019183148-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | KNOPP BIOSCIENCES LLC (US) | 2019-09-26 | — | — | WO | disclosed |